Pyronaridine-artesunate With Low Dose Primaquine for Preventing P. Falciparum Transmission
Status:
Completed
Trial end date:
2020-01-07
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the gametocytocidal and transmission reducing activity
of pyronaridine-artesunate (PA) and dihydroartemisinin-piperaquine (DP) with and without a
single low dose of primaquine (PQ; 0.25mg/kg). Outcome measures will include infectivity at 2
and 7 days after treatment, the duration of infectivity in the artemisinin combination
therapy (ACT) only arms, and the production and detectability of histidine rich protein II.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
London School of Hygiene and Tropical Medicine
Collaborators:
Malaria Research and Training Center, Bamako, Mali Radboud University